Amino.Desk

Khavinson short peptides: Bronchogen, Cardiogen and seven more

Updated Nov 17, 2026 · Clinical review: pending

This page covers nine Russian short peptides that are each sold for a single organ: Bronchogen, Cardiogen, Chonluten, Crystagen, Livagen, Ovagen, Pancragen, Prostamax and Testagen. They belong to the family known as Khavinson bioregulators. We found no controlled human trial of any of the nine, and none has a lawful route in the US.

What they are

Beginning in the 1970s, Vladimir Khavinson's group in St. Petersburg extracted peptide mixtures from animal organs, then made short synthetic peptides meant to reproduce each extract's effect. The idea is that every organ makes its own short regulatory peptides, and that supplying them restores that organ. The synthetic versions are what research suppliers sell.

Members of the family with more of a record have their own pages: Epitalon, Pinealon, Vilon, Cortagen, Cartalax and Vesugen, and the registered Russian drugs Thymalin and Thymogen.

The nine on this page

PeptideSold forHuman trial evidence
BronchogenBronchial and lung support.None found.
CardiogenHeart support.None found.
ChonlutenLung and airway support. Also spelled Choluten.None found.
CrystagenImmune support.None found.
LivagenLiver support and anti-aging.None found.
OvagenLiver and digestive support.None found.
PancragenPancreas and blood sugar support.None found.
ProstamaxProstate support.None found.
TestagenTesticular and hormone support.None found.

The target organ in each case is the seller's and developer's description. It is not a tested medical use.

What the evidence shows

We found no controlled human trial of any of these nine peptides in the sources we reviewed.

For the family as a whole, the record is cell experiments, rodent studies, and small, often unblinded human studies run by the original group. Key findings have not been reproduced by independent teams. The most-cited human study, a 266-person cohort followed for six to eight years, tested thymus and pineal extracts, not these peptides, and was not blinded.

A result in a cell dish shows a possible pathway. It is the kind of evidence furthest from showing that a compound does anything in a living person.

Legal status

Reported dosing

We do not publish a protocol for these compounds.

No dose has been established in a controlled human trial for any of them. The course schedules that circulate come from the developers' own tradition and from sellers.

Safety

Common questions

What are Khavinson bioregulators?

A family of short peptides developed in Russia, each marketed for a particular organ.

Are Bronchogen, Cardiogen or the others FDA-approved?

No. None of the nine is approved, and none is eligible for pharmacy compounding.

Have these peptides been tested in people?

We found no controlled human trial of any of the nine. The family's evidence is cell and animal work and small unblinded studies from its developers.

Which bioregulator has the most evidence?

Epitalon is the most studied of the short peptides. Thymalin and Thymogen are registered drugs in Russia.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy